



PATENT
2543-1-031

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Herath Mudiyansele Athula Chandrasiri Herath et al.

SERIAL NO.: 10/700,330

EXAMINER: Unassigned

DATE FILED: November 3, 2003

ART UNIT: Unassigned

FOR: PROTEINS AND GENES FOR DIAGNOSIS AND TREATMENT OF
ErbB2-RELATED CANCER

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA on November 24, 2003.

Karen Garipoli
(Name of Depositor)

Karen Garipoli 11/24/03
(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References AA through CI listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

David A. Jackson
David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-031
	SERIAL NO.	10/700,330
	APPLICANT	HERATH et al
	FILING DATE	November 3, 2003
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,914,238	6/22/99	Keese et al			
	AB	6,064,754	5/16/00	Parekh et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
	BA	WO 01/13117 A2	2/22/01	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Harris, R.A,etal.,New Model of ErbB-2 Over-Expression in Human Mammary Luminal Epithelial Cells, Int. J. Cancer; 80, (1999), Pgs. 477-484
	CB	Lumachi,F.,etal,Long-Term Follow-up Study in Breast Cancer Patients Using Serum Tumor Markers CEA and CA 15-3, Anticancer Research 19; (1999), Pgs. 4485-4490
	CC	Ross,J.,etal,The HER-2/ <i>neu</i> Oncogene in Breast Cancer:Prognostic Factor, Predictive Factor, and Target for Therapy; The Oncologist, (1998), Pgs. 237-252
	CD	Page, M.J.,etal,Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties, PNAS, Vol 96,No.22,(1999),Pgs. 12589-12594
	CE	Page,M.J.,etal,Proteomics: a major new technology for the drug discovery process, DDT Vol 4, No. 2, (1999), Pgs. 55-62
	CF	Ross,JS, etal, The HER-/ <i>neu</i> oncogene: prognostic factor, predictive factor and target for therapy, Cancer Biology, Vol. 9, (1999), Pgs. 125-138
	CG	Lessor,TJ,etal,Ectopic Expression of the ErbB-3 Binding Protein Ebp1 Inhibits Growth and Induces Differentiation of Human Breast Cancer Cell Lines,Jour of Cell Phys,(2000) 321-29
	CH	Bruening,W,etal,Synucleins Are Expressed in the Majority of Breast Cancer and Ovarian Carcinomas and in Preneoplastic Lesions of the Ovary,Amer.Cancer Soc.(2000) 2154-2163
	CI	Ouchi,T,etal,Collaboration of signal transducer and activator of transcription 1(STAT1)and BRCA1 in differential regulation of IFN- γ target genes,PNAS,Vol.97,No.10(2000) 5208-213
EXAMINER:		DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		